APD668: Phase I started

JNJ's subsidiary, Ortho-McNeil Pharmaceutical Inc. (Raritan, N.J.), started a double-blind, placebo-controlled, dose-escalation Phase I trial in healthy volunteers. The start of the trial triggered a...